Actively Recruiting
Evaluating PDS01ADC Alone and With M7824 for Advanced Kaposi Sarcoma An Open-Label Study of Immune-Based Treatments for KS
Led by National Cancer Institute (NCI) · Updated on 2026-10-16
80
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Kaposi Sarcoma KS is a tumor that can grow on the skin, lymph nodes, lungs, bones, and gastrointestinal tract. It often affects people with weakened immune systems, such as those living with HIV or with a history of organ transplant. This study evaluates the use of two non-chemotherapy drugs, PDS01ADC and M7824, to see if they can help the immune system fight KS tumors, especially in patients who have received prior treatments. Participants will receive PDS01ADC by injection under the skin every 4 weeks for up to 96 weeks or 24 cycles. Some participants will also receive M7824 through an intravenous tube every 2 weeks for the same duration. The study includes a monotherapy group receiving PDS01ADC alone and a combination group receiving both drugs. Dose adjustments may occur based on safety, and treatment continues until tumors stop responding, unacceptable side effects occur, or up to 24 cycles. During the study, participants will undergo various assessments including physical exams, imaging scans, blood and urine tests, lung function tests, and biopsies of KS lesions. Researchers will measure tumor size, take photographs, collect saliva and tissue samples, and assess quality of life and daily activities. Follow-up visits will occur 7 and 30 days after treatment ends, then every 3 to 6 months for 18 months, and annually for 3 years to monitor outcomes and safety.
CONDITIONS
Brief Title
PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma
Research Team
I
Irene B Ekwede, R.N.
R
Ramya M Ramaswami, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here